Program
mecobalamin
Also written as “E0302 (mecobalamin)”, “Methylconalamin Injection(WP205)” and “Methylcobalamin Injection(WP205)”.
Its studies are mostly in Amyotrophic Lateral Sclerosis · Dementia · Peripheral Nervous System Diseases, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisai | 60 open or running | phase 4since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Wanbangde Pharmaceutical Group | 20 open or running | phase 1since Aug 27, 2025 | Aug 27, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 12, 2005First study: phase 4 study in Dementia With Vitamin B12 DeficiencyNew to EisaiEisai · NCT00165711 · China
- Mar 6, 20072 phase 3 studies in Amyotrophic Lateral SclerosisEisai · NCT00445172, NCT00444613
- Aug 26, 2010Phase 4 study in Peripheral Nervous System DiseasesEisai · NCT01192113 · 1,072 enrolled · China
- May 14, 2018Phase 3 study in Amyotrophic Lateral SclerosisEisai · NCT03548311 · 130 enrolled · Japan
- Mar 6, 2019Phase 1 study in Healthy SubjectsEisai · NCT03885882 · 24 enrolled · New Zealand
- Aug 27, 2025Wanbangde Pharmaceutical Group's first study: phase 1 study in Therapeutic Equivalency, HealthyNew to Wanbangde Pharmaceutical GroupWanbangde Pharmaceutical Group · NCT07158099 · 14 enrolled · China
- Nov 19, 2025Phase 1 study in Therapeutic Equivalency, HealthyWanbangde Pharmaceutical Group · NCT07281872 · 20 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07281872Therapeutic Equivalency, Healthy · China | 1 | Completed | Wanbangde Pharmaceutical Group | Nov 6, 2025 | 20 |
| NCT07158099Therapeutic Equivalency, Healthy · China | 1 | Completed | Wanbangde Pharmaceutical Group | Sep 18, 2025 | 14 |
| NCT03885882Healthy Subjects · New Zealand | 1 | Completed | Eisai | Jun 26, 2019 | 24 |
| NCT03548311Amyotrophic Lateral Sclerosis · Japan | 3 | Completed | Eisai | Feb 14, 2020 | 130 |
| NCT01192113Peripheral Nervous System Diseases · China | 4 | Completed | Eisai | May 2011 | 1,072 |
| NCT00445172Amyotrophic Lateral Sclerosis · Japan | 3 | Completed | Eisai | Mar 31, 2017 | 135 |
| NCT00444613Amyotrophic Lateral Sclerosis · Japan | 3 | Completed | Eisai | Mar 2014 | 373 |
| NCT00165711Dementia With Vitamin B12 Deficiency · China | 4 | Completed | Eisai |
How it is read
Names in the registry
- “E0302 (mecobalamin)”, 3 entries
- “Methylconalamin Injection(WP205)”, 1 entry
- “Methylcobalamin Injection(WP205)”, 1 entry
- “Methylcobalamin for Injection”, 1 entry
- “methylcobalamin”, 1 entry
Codes read as this program: WP205, E0302.
Conditions, from the studies’ own filings
- Amyotrophic Lateral Sclerosis, 3 studies
- Dementia, 1 study
- Peripheral Nervous System Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.